↓ Skip to main content

First-in-man tau vaccine targeting structural determinants essential for pathological tau–tau interaction reduces tau oligomerisation and neurofibrillary degeneration in an Alzheimer’s disease model

Overview of attention for article published in Alzheimer's Research & Therapy, August 2014
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (94th percentile)
  • High Attention Score compared to outputs of the same age and source (87th percentile)

Mentioned by

news
2 news outlets
blogs
1 blog
twitter
1 X user
patent
3 patents
wikipedia
2 Wikipedia pages

Citations

dimensions_citation
200 Dimensions

Readers on

mendeley
217 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
First-in-man tau vaccine targeting structural determinants essential for pathological tau–tau interaction reduces tau oligomerisation and neurofibrillary degeneration in an Alzheimer’s disease model
Published in
Alzheimer's Research & Therapy, August 2014
DOI 10.1186/alzrt278
Pubmed ID
Authors

Eva Kontsekova, Norbert Zilka, Branislav Kovacech, Petr Novak, Michal Novak

Abstract

We have identified structural determinants on tau protein that are essential for pathological tau-tau interaction in Alzheimer's disease (AD). These regulatory domains, revealed by monoclonal antibody DC8E8, represent a novel target for tau-directed therapy. In order to validate this target, we have developed an active vaccine, AADvac1.

X Demographics

X Demographics

The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 217 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Spain 2 <1%
United States 1 <1%
Unknown 214 99%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 45 21%
Researcher 39 18%
Student > Master 33 15%
Student > Ph. D. Student 26 12%
Student > Postgraduate 9 4%
Other 21 10%
Unknown 44 20%
Readers by discipline Count As %
Agricultural and Biological Sciences 36 17%
Neuroscience 33 15%
Biochemistry, Genetics and Molecular Biology 29 13%
Medicine and Dentistry 20 9%
Chemistry 16 7%
Other 32 15%
Unknown 51 24%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 32. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 30 June 2022.
All research outputs
#1,241,551
of 25,463,724 outputs
Outputs from Alzheimer's Research & Therapy
#167
of 1,471 outputs
Outputs of similar age
#12,122
of 240,290 outputs
Outputs of similar age from Alzheimer's Research & Therapy
#3
of 16 outputs
Altmetric has tracked 25,463,724 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 95th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,471 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 26.6. This one has done well, scoring higher than 88% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 240,290 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 94% of its contemporaries.
We're also able to compare this research output to 16 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 87% of its contemporaries.